1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes care, 27(2), 596–601.
2. Anglin, G., Swinburn, A., Foster, L., Brach, C., Bergofsky, L. (2014). The national evaluation of the CHIPRA quality demonstration grant program. Implementation guide number 2: Designing care management entities for youth with complex behavioral health need. Retrieved from
http://www.ahrq.gov/sites/default/files/publications/files/impguide2.pdf
.
3. APA Working Group on Psychoactive Medications for Children and Adolescents. (2006). Report of the working group on psychoactive medications for children and adolescents. Psychopharmacological, psychosocial, and combined interventions for childhood disorders: Evidence base, contextual factors, and future directions. Washington, DC: American Psychological Association.
4. Bobo, W. V., Cooper, W. O., Stein, C. M., Olfson, M., Graham, D., Daugherty, J., Ray, W. A. (2013). Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry, 70(10), 1067–1075. doi:
10.1001/jamapsychiatry.2013.2053
.
5. Bruns, E. J., Rast, J., Peterson, C., Walker, J., & Bosworth, J. (2006). Spreadsheets, service providers, and the statehouse: Using data and the wraparound process to reform systems for children and families. American Journal of Community Psychology, 38(3–4), 201–212. doi:
10.1007/s10464-006-9074-z.
.